Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in CLL?
Cello Health plc: THE INVESTMENT CASE

Cello Group has scope for re-rating once it proves itself says broker

Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006
Cello
INVESTMENT OVERVIEW: CLL The Big Picture
Mark Scott, Cello Group

A name change to Cello Health Group PLC (LON:CLL) highlights the shift in focus underway at the specialist marketing group.

Brands have been unified under the new name to establish a broad, cohesive service across of its platforms.

WATCH: Cello Group name change reflects growing credibility in healthcare, says CEO Scott

House broker finncap says the aim is to help the pharma majors drug development programmes through assessing market opportunities, commercial risk and routes to market.

While you might think these juggernauts do all this for themselves, finncap adds this is not the case and the market for Cello’s technically based, strategic marketing services is strong and defensive.

Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006.

Double-digit growth

“The evidence from competitors is that double-digit earnings growth is readily achievable and will be rewarded by a P/E of 20x+,” said the broker.

That would amount to a substantial re-re-rating of the share price, as on the broker’s forecasts for adjusted profits this year (2018) the rating is around 13 at 113p.

In 2017, revenues rose 2% to £169.3mln, and by 2.5% like-for-like, while underlying profits were 12% better at £11.4mln.

Pre-tax profits came in at £5.8mln against a loss of £1.7mln while there was a dividend of 3.5p.

Cello Health picked up 49 new clients in 2017 and has now worked with 24 of the top 25 pharmaceutical companies.

The US contributed 45% of Cello Health's gross profit and 30% of group gross profit, with a stronger dollar also helping last year.

Signal, Cello’s other division, saw its profit contribution dropped to £3.87mln as two contracts in 2016 did not repeat.

Going forward it will focus more on support for the health business.

Broker sees clear opportunity

Cello has to prove the benefits of the shift towards health, adds finncap, but with net cash and the potential also to leverage its digital expertise into health there is clear opportunity.

The company had net cash of £1.6mln at December and debt facilities of £20mln.

That is is enough firepower for more acquisitions and though high valuations are a challenge, and management has a strict focus on value, bolt-ons should support the growth story, adds the broker.

"For now, we value Cello at a 20% discount to peers, setting a 145p target."

“As the growth potential is proved, we should be able to remove the discount.”

 

 

 

View full CLL profile View Profile

Cello Health plc Timeline

Related Articles

Media junkie
February 14 2018
In modern parlance, Ebiquity is making a pivot towards becoming the "world's leading tech-enabled marketing and media analytics consultancy"
Apollo 11
February 22 2018
Immersive VR, a technology company focused on the education space, was the first company Sure backed
Throne of Glass
April 30 2018
Rowling, Rowling, Rowling ... keep those titles rolling. Mind you, it's not all about Ms Rowling; Sarah J Maas title revenues grew 47% in the first half of the financial year and dieters are gorging on Tom Kerridge's books

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use